Updated guidelines for the treatment of advanced BC suggest that cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy improve the overall survival (OS) of patients; however, most patients eventually develop acquired drug resistance to CDK4/6i [2]. Here, CDK4 is linked to breast cancer.